Global Oligonucleotide Therapeutics Market, By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others) – Industry Trends and Forecast to 2029.
Global Oligonucleotide Therapeutics Market Analysis and Size
Oligonucleotide therapeutics are known to inhibit the expression of certain genes that is different from conventional medicine. In past years, innovative new oligonucleotides have been developed that are capable of targeting specific genes and treat chronic diseases.
- Chemically modified artificial nucleic acids are utilized for the development of oligonucleotide therapeutics. Global Oligonucleotide Therapeutics Market was valued at USD 18.19 billion in 2021 and is expected to reach USD 51.35 billion by 2029, registering a CAGR of 13.85% during the forecast period of 2022-2029. “Infectious Diseases” is expected to witness high growth owing to increase in the number of infectious diseases, such as COVID-19. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Oligonucleotide Therapeutics Market Definition
Oligonucleotides refer to the short chain RNA or DNA that are generally manufactured by making the use of automated synthesizers. Anion exchange chromatography which is followed by desalting and freezing technique is done for the purification of the oligonucleotide.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
BPCI Biotech Holding (Norway), SomaGenics Inc (US), Hepion Pharmaceuticals (US), Alnylam Pharmaceuticals (US), Regulus Therapeutics Inc (US), Ionis Pharmaceuticals (US), Gilead Sciences, Inc (US), Santaris (Denmark), InteRNA Technologies B.V. (Netherlands), Mirage (US), Biogen (US), Merck KgaA (Germany), and Pfizer Inc. (US), among others
|
|
Market Opportunities
|
|
Oligonucleotide Therapeutics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
-
Infectious Diseases
The increase in the prevalence of infectious diseases, such as coronavirus, chickenpox, common cold, and diphtheria, among others acts as one of the major factors driving the growth of oligonucleotide therapeutics market.
-
Increase in Mergers and Acquisitions
The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.
-
Up-Gradation
The development of more stable and extended half-life molecules owing to the technological upgrades of chemically synthesized oligonucleotides further influence the market.
Opportunities
Furthermore, launch of innovative and technologically advanced products to meet the needs of customers extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, surge in investments will further expand the market.
Restraints/Challenges Global Oligonucleotide Therapeutics Market
On the other hand, incapability to detect minor antibodies is expected to obstruct market growth. Also, stringent regulations are projected to challenge the oligonucleotide therapeutics market in the forecast period of 2022-2029.
This oligonucleotide therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on oligonucleotide therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Oligonucleotide Therapeutics Market
COVID-19 had a negative impact on the healthcare sector. Major Key players adapted innovative strategies to the rapidly changing situation during the outbreak of the COVID-19. Countries took critical healthcare changes until the crisis took a back seat. Healthcare reforms are expected to witness cost containment, increased access and technological progress in the coming years. . The implementation of social distancing, lockdown of the population and limited access to clinics greatly affected the market. The slow-down in patient flow and referrals, and decline in trauma and workplace injuries also impacted the market growth. However, market will resume its growth in the post-pandemic due to the easing in restrictions that were imposed earlier.
Global Oligonucleotide Therapeutics Market Scope and Market Size
The degenerative disc disease market is segmented on the basis of type and application. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antisense
- Ribozymes
- Aptamers
- Mirna
- Cpg/Immunostimulatory
- RNAi
Based on type, the oligonucleotide therapeutics market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory and RNAi.
Application
- Infectious Diseases
- Oncology
- Neurodegenerative Disorders
- Cardiovascular Diseases
- Kidney Diseases
- Others
Based on application, the oligonucleotide therapeutics market is segmented into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others.
Oligonucleotide Therapeutics Market Regional Analysis/Insights
The oligonucleotide therapeutics market is analysed and market size insights and trends are provided by country, type and application as referenced above.
The countries covered in the oligonucleotide therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the oligonucleotide therapeutics market because of the rise in the prevalence of chronic diseases within the region.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the surge in demand for advanced technologies in oligonucleotide therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The oligonucleotide therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for oligonucleotide therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the oligonucleotide therapeutics market. The data is available for historic period 2010-2020.
Competitive Landscape and Oligonucleotide Therapeutics Market Share Analysis
The oligonucleotide therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to oligonucleotide therapeutics market.
Some of the major players operating in the oligonucleotide therapeutics market are
- PCI Biotech Holding (Norway)
- SomaGenics Inc (US)
- Hepion Pharmaceuticals (US)
- Alnylam Pharmaceuticals (US)
- Regulus Therapeutics Inc (US)
- Ionis Pharmaceuticals (US)
- Gilead Sciences, Inc (US)
- Santaris (Denmark)
- InteRNA Technologies B.V. (Netherlands)
- Mirage (US), Biogen (US)
- Merck KgaA (Germany)
- Pfizer Inc. (US)
SKU-